Ms. Linda Kisa reports

CRESCITA THERAPEUTICS ANNOUNCES APPROVAL OF NORMAL COURSE ISSUER BID

The Toronto Stock Exchange has approved Crescita Therapeutics Inc.'s proposed normal course issuer bid (NCIB) to purchase up to a maximum of 1,478,854 common shares for cancellation, representing approximately 10 per cent of its public float as of Sept. 16, 2024, as appropriate opportunities arise from time to time. As of Sept. 16, 2024, the company had 19,186,136 issued and outstanding common shares.

Crescita's management and board of directors believe that the current market price of the common shares may not represent the underlying value of the company, and has determined that, subject to future price movements and other factors, the repurchase of such common shares may be a desirable use of funds and in the best interests of the company and its shareholders.

Purchases under the NCIB will be made through the facilities of the TSX or through a Canadian alternative trading system and in accordance with applicable regulatory requirements at a price per common share representative of the market price at the time of acquisition. The number of common shares that can be purchased pursuant to the NCIB is subject to a current daily maximum of 3,682 common shares (equal to 25 per cent of 14,731 being the average daily trading volume from March 1, 2024, through to Aug. 31, 2024), subject to the company's ability to make one block purchase of common shares per calendar week that exceeds such limits. All common shares purchased under the NCIB will be cancelled upon their purchase. The company intends to finance the purchases from its available resources.

The company may begin to purchase common shares on Sept. 27, 2024, and the NCIB will terminate on Sept. 26, 2025, or such earlier time as the company completes its purchases pursuant to the NCIB or provides notice of termination. The company has also entered into an automatic securities purchase plan in connection with its NCIB that contains strict parameters regarding how its common shares may be repurchased during times when it would ordinarily not be permitted to purchase common shares due to regulatory restrictions or self-imposed blackout periods. The automatic securities purchase plan is effective on Sept. 27, 2024.

Pursuant to the company's previous normal course issuer bid that commenced on Aug. 31, 2023, and ended on Aug. 30, 2024, 1,188,017 common shares were purchased at a weighted average price of 53 cents per share. Purchases were made on behalf of the company by its broker through the facilities of the Toronto Stock Exchange. Crescita was permitted to acquire up to 1,821,616 common shares under its previous normal course issuer bid.

About Crescita Therapeutics Inc.

Crescita is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D (research and development) and manufacturing capabilities. The company offers a portfolio of high-quality, science-based non-prescription skin care products and a commercial-stage prescription product. The company also owns multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin.

We seek Safe Harbor.